Glycophos

Glycophos is an intravenous solution containing sodium glycerophosphate pentahydrate as its active ingredient. It is supplied in a sterile liquid form for parenteral administration and marketed in the European Union as a prescription‑only product. The preparation provides phosphate and sodium ions to support metabolic processes and cellular function. It is packaged in single‑use vials for hospital or clinical use to correct phosphate deficits effectively and safely.

Glycophos is indicated for the treatment and prevention of conditions associated with low phosphate levels in the body. It is used when phosphate depletion occurs due to medical conditions, surgery, or prolonged intravenous nutrition, and when rapid correction of phosphate is required.

- Hypophosphatemia resulting from renal loss, malnutrition, or critical illness. - Phosphate depletion during total parenteral nutrition (TPN) therapy. - Replenishment of phosphate after extensive blood transfusions. - Support of bone mineralization in patients with chronic phosphate deficits. - Adjunct therapy in postoperative patients to maintain electrolyte balance.

Intravenous administration of Glycophos may be associated with a range of adverse reactions, most of which are mild and transient, while rare serious events can also occur.

Common: - Mild nausea or vomiting. - Transient headache or dizziness. - Local irritation at the infusion site. - Temporary rise in serum calcium levels. - Mild hypernatremia. - Flushing or warmth sensation. - Mild muscle cramps.

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Acute allergic reaction or anaphylaxis. - Significant electrolyte imbalance causing cardiac arrhythmia. - Renal failure exacerbation due to phosphate overload. - Metabolic acidosis.

Before initiating Glycophos therapy, clinicians should evaluate patient history, laboratory values, and potential risk factors to minimize complications and ensure appropriate use.

- Verify serum phosphate, calcium, and sodium levels prior to infusion. - Adjust dose in patients with renal impairment or chronic kidney disease. - Monitor cardiac function and ECG in patients at risk for arrhythmias. - Avoid rapid infusion rates that may cause precipitation of calcium‑phosphate complexes. - Use caution in individuals with known hypersensitivity to glycerophosphate compounds. - Reassess electrolyte status regularly during and after treatment.

Glycophos can interact with other medications or solutions that affect electrolyte balance, calcium metabolism, or renal function, requiring careful management to prevent adverse outcomes.

Avoid: - Concomitant administration with calcium-containing IV solutions. - Use with high-dose vitamin D supplements that increase calcium absorption. - Simultaneous infusion of other phosphate salts without dose adjustment.

Use with caution: - Loop diuretics that may alter sodium and phosphate excretion. - ACE inhibitors or ARBs in patients with renal insufficiency. - Antacids containing aluminum or magnesium that affect phosphate absorption.